Compare Altria Group Inc (MO) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Smith & Nephew plc — how do they compare? Altria Group Inc trades at $68.02 (market cap $113.83B), while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Altria Group Inc is far larger — about 9.8× Smith & Nephew plc's market cap, and Altria Group Inc pays the higher dividend (6.51%). Which is the better fit depends on your goals.
| MO | SNN | |
|---|---|---|
Market Cap | $113.83B | $11.63B |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $38.53 |
52-Week Low | $54.72 | $27.80 |
Enterprise Value | $136.04B | $14.66B |
Dividend Yield | 6.51% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $68.18, down 1.02% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock offers a high dividend yield of 6.45% following its 61st annual increase. Recent earnings show mixed quarterly results, with Q1 2026 beating expectations but Q2 2026 missing. Revenue remains stable around $20.1 billion (2025), with strong profitability margins, though net income declined to $6.95 billion in 2025 from $11.3 billion in 2024. Analyst consensus is bullish with a $68.50 price target.
MO presents a value opportunity with a low P/E of 14.35 and robust cash flows supporting dividends, but faces risks from regulatory lawsuits, declining cigarette volumes, and high debt levels. The stock's appeal hinges on dividend sustainability amid secular challenges in the tobacco industry.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
